TY - JOUR AU - Heideman, Marinus R. AU - Hynes, Nancy E. PY - 2013 DA - 2013/10/29 TI - AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors? JO - Breast Cancer Research SP - 315 VL - 15 IS - 5 AB - Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. Reasons for these results have remained elusive. Recently, Meyer and colleagues showed interplay between EGFR and the epithelial-to-mesenchymal transition-associated AXL receptor in TNBC cells, which might provide some clues. SN - 1465-542X UR - https://doi.org/10.1186/bcr3564 DO - 10.1186/bcr3564 ID - Heideman2013 ER -